Bristol-Myers Squibb‘s Opdivo (nivolumab) is superior to chemotherapy for treating patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) that cannot be removed surgically, and who are resistant or intolerant to combination therapy with fluoropyrimidine and platinum-based treatments, the ATTRACTION-3 clinical trial shows. Opdivo demonstrated a significant improvement over chemotherapy, with a 23% reduction … Continue reading Opdivo Superior to Chemotherapy in Patients with Advanced Esophageal Cancer, Trial Shows